Vivos Therapeutics, Inc. closed a private placement (PIPE Offering) on June 30, 2026, raising approximately $2.1 million. The offering involved the sale of 3,608,496 units at $0.582 per unit. Each unit comprised one share of Series A Convertible Preferred Stock, common stock purchase warrants, and two transferable subscription rights. The company received $1 million in cash proceeds, with an additional $1 million from the conversion of a previously issued bridge note. The net proceeds are intended for general working capital purposes. The Series A Convertible Preferred Stock is convertible into common stock on a one-for-one basis, subject to adjustments and beneficial ownership limitations. The warrants have an exercise price of $0.456 per share, a five-year term, and include anti-dilution protection. Beneficial ownership limitations are in place for V-Co 4 (19.99%) and Bigger Capital Fund (9.99% or 4.99%). The company is obligated to file a resale registration statement for the convertible preferred stock and warrant shares within 45 days of closing and have it declared effective within 90 days.